Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

Blood

Volumn 113, Issue 20, 2009, Pages 4977-4979

  Pérez Andreu, Virginia ^a   Roldán, Vanessa ^a   Antón, Ana Isabel ^a   García Barberá, Nuria ^a   Corral, Javier ^a   Vicente, Vicente ^a   González Conejero, Rocio ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CYTOCHROME P 450 F2; CYTOCHROME P450; PROTHROMBIN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; CYP4F2 PROTEIN, HUMAN; MENADIONE EPOXIDASE; METHIONINE; MIXED FUNCTION OXIDASE; VALINE;

ADULT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE INCREASE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE; AGED; BLOOD CLOTTING TEST; CLINICAL TRIAL; DOSE CALCULATION; DRUG RESISTANCE; GENETICS; GENOTYPE; MIDDLE AGED; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME;

ACENOCOUMAROL; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; VALINE;

EID: 66549110050     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-176222     Document Type: Article

References (17)

1. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population-based study. Ann Intern Med. 1999;5:130:14-22.
2. Evans A, Davis S, Kilpatrick C, Gerraty R, Campbell D, Greenberg P. The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci. 2002;9:268-272. (Pubitemid 34885563)
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133(suppl 6):160S-198S. (Pubitemid 351892962)
4. Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol. 2006;62:617-620.
5. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
6. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112:1022-1027.
7. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784-792.
8. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;15:111:4106-4112.
9. González-Conejero R, Corral J, Roldán V, et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007;5:1701-1706. (Pubitemid 47091414)
10. González-Conejero R, Corral J, Roldán V, Vicente V. Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. Thromb Res. 2008;122:429-431.
11. Fava C, Montagnana M, Almgren P, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-380.
12. Bernardi F, Arcieri P, Bertina RM, et al. Contribution of factor VII genotype to activated FVII levels: differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol. 1997;17:2548-2553. (Pubitemid 28015992)
13. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status. J Biol Chem. 2002;12:277:25290-25296.
14. Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;51:1393-1398. (Pubitemid 351555955)
15. Thacker SM, Grice GR, Milligan PE, Gage BF. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. J Thromb Haemost. 2008;6:1445-1449.
16. Mannucci PM, Spreafico M, Peyvandi F. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. J Thromb Haemost. 2008;6:1450-1452.
17. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009;113:3925-3930.